Results 71 to 80 of about 14,668 (165)
Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay
Daratumumab, a monoclonal antibody used to treat relapsed or refractory multiple myeloma, can interfere with protein electrophoresis and immunofixation assays.
Ramanathan, Lakshmi V +4 more
core +1 more source
Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies
Sathish Gopalakrishnan,1 Daryl Tan1,2 1Department of Hematology, Singapore General Hospital, Singapore, Republic of Singapore; 2Raffles Cancer Center, Raffles Hospital, Singapore, Republic of Singapore Abstract: Although the clinical outcomes of patients
Gopalakrishnan S, Tan D
core
Daratumumab is an anti-CD38 monoclonal antibody that has shown clinical benefit in both relapsed/refractory as well as newly diagnosed multiple myeloma (MM).
Guido Lancman +13 more
doaj +1 more source
Daratumumab is an anti-CD38 fully human IgG1 mAb approved for multiple myeloma treatment. One of the proposed mechanisms of action is the induction of antibody-dependent cellular cytotoxicity (ADCC) mediated by NK cells.
Maria C. Ochoa +15 more
doaj +1 more source
Introduction. Patients with high-risk smoldering multiple myeloma (SMM) may benefit from early treatment. With SMM risk stratification advancement, post hoc analysis of the AQUILA study using IMWG 2020 (“20/2/20”) and other risk models was conducted to ...
F. Schjesvold +38 more
doaj +1 more source
Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma:CASSIOPEIA minimal residual disease results [PDF]
Previous results from CASSIOPEIA demonstrated superior progression-free survival (PFS) and minimal residual disease (MRD) negativity with the addition of daratumumab to bortezomib, thalidomide, and dexamethasone (VTd) induction/consolidation and with ...
Rowe, Melissa +31 more
core +1 more source
Background Daratumumab is a human IgGκ monoclonal antibody targeting CD38 with direct on-tumor and immunomodulatory mechanisms of action. Daratumumab-based treatment is a standard of care for multiple myeloma (MM) based on data from randomized controlled
Luqun Wang +17 more
doaj +1 more source
ABSTRACT Light chain monoclonal gammopathy of undetermined significance (LC‐MGUS) is defined by an abnormal serum free light chain ratio and elevated involved light chain in the absence of a detectable immunoglobulin heavy chain on immunofixation and of end‐organ damage attributable to a plasma cell disorder.
Sigurður Yngvi Kristinsson +2 more
wiley +1 more source
Daratumumab: a game changer in early myeloma
In this issue of Blood, Landgren et al1 report on the efficacy and safety of daratumumab in smoldering multiple myeloma (SMM). Daratumumab was the first anti-CD38 monoclonal antibody to demonstrate efficacy as a single agent in treating patients with ...
González-Calle, Verónica +1 more
core +1 more source
Despite recent treatment improvements, multiple myeloma remains an incurable disease. Since antibody-dependent cell-mediated cytotoxicity is an important effector mechanism of daratumumab, we explored the possibility of improving daratumumab-mediated ...
Inger S. Nijhof +8 more
doaj +1 more source

